There have been major advances in the immunotherapy of cancer in recent years, including
the development of T cell engagers—antibodies engineered to redirect T cells to recognize …

Despite the clinical success of the first bispecific antibody approved by the FDA against B
cell malignancies (blinatumomab), many obstacles remain such as dosing, treatment …

Costimulatory receptors on immune cells represent attractive targets for immunotherapy
given that these molecules can increase the frequency of individual protective immune cell …

Bispecific antibodies (bsAbs) are engineered molecules designed to target two different
epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets …

Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding
activity, which permits simultaneous targeting of antigens and synergistic binding effects …

Melittin, as an agent to lyse biological membranes, may be a promising therapeutic agent in
the treatment of cancer. However, because of its nonspecific actions, there is a need to use a …

ABSTRACT T cell-based immunotherapies for solid tumors have not achieved the clinical
success observed in hematological malignancies, partially due to the immunosuppressive …

Immune checkpoint blockade has changed the treatment paradigm for advanced solid
tumors, but the overall response rates are still limited. The combination of checkpoint …

Le récepteur ILT4 est un point de contrôle immunitaire, principalement exprimé par les
cellules myéloïdes du système immunitaire. Dans le contexte cancéreux, ILT4 participe au …